sun pharma q2fy25 results preview net profit pat revenue growth ebitda margin what to expect share market nse bse dilip shanghvi

Headquartered successful Mumbai, the pharma large Sun Pharma is acceptable to merchandise its July-September results aft marketplace hours today. Zee Business probe estimates consolidated PAT for the reappraisal play to turn by 11.5 per cent year-on-year (YoY) to Rs 2,649 crore connected the backmost of improved India business. In the aforesaid 4th past year, the company's nett net stood astatine Rs 2,376 crore. 

The topline astatine the institution is besides seen to registry 8 per cent on-year maturation during the July-September 4th and travel successful astatine Rs 13,191 crore. In the corresponding play past year, the institution reported gross astatine Rs 12,192 crore.

EBITDA or earnings earlier interest, taxes, depreciation, and amortization is estimated to witnesser 12 per cent maturation to Rs 3,610 crore arsenic against Rs 3,214 crore reported successful the aforesaid play a year-ago. Meanwhile, EBITDA borderline is seen edging higher to 27.4 per cent during the reporting quarter, a 1 per cent oregon 100 bps summation implicit the aforesaid play past year.

Furthermore, the US income astatine the planetary specialty generic pharma institution are estimated astatine US$482 million, portion gross from the home concern is expected to emergence 10 per cent on-year during the reappraisal quarter. 

However, successful the RoW (Rest of World) and emerging markets business, Zee Busines analysts peg maturation to the tune of 4 per cent successful the cause major's revenue. RoW  is 1 of the segments successful Sun Pharmaceutical Industries Limited's (Sun Pharma) business.

Furthermore, analysts expect an betterment successful the company's gross margins during Q2. 

Key monitorable

Investors volition support a adjacent ticker connected the caller launches astatine the pharma major.

Sun Pharma's Q1FY25 results 

For the June quarter, the company's consolidated nett net zoomed 40 per cent on-year to Rs 2,836 crore versus Rs 2,022 crore reported during the aforesaid play past year. Also, gross from operations during the play roseate 6 per cent to Rs 12,653 crore.

Sun Pharma's stock terms performance

In the past year, shares of Sun Pharma person outperformed Nifty Pharma with a instrumentality of arsenic overmuch arsenic 68.5 per cent.